InvestorsHub Logo
Followers 139
Posts 23249
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Thursday, 03/18/2021 8:58:37 PM

Thursday, March 18, 2021 8:58:37 PM

Post# of 463611
The Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD) could complete enrollment within the next week or two.

With over 40 sites currently recruiting enrollment is nearly complete as stated by Dr. Missling.

https://www.anavex.com/anavex-life-sciences-reports-fiscal-2021-first-quarter-financial-results-and-business-outlook/

Good luck and GOD bless,

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News